MA31536B1 - Sels d'amines d'un antagoniste de crth2 - Google Patents

Sels d'amines d'un antagoniste de crth2

Info

Publication number
MA31536B1
MA31536B1 MA32540A MA32540A MA31536B1 MA 31536 B1 MA31536 B1 MA 31536B1 MA 32540 A MA32540 A MA 32540A MA 32540 A MA32540 A MA 32540A MA 31536 B1 MA31536 B1 MA 31536B1
Authority
MA
Morocco
Prior art keywords
salts
amines
crth2 antagonist
crth2
ceetic
Prior art date
Application number
MA32540A
Other languages
English (en)
Inventor
Tai Wei Ly
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31536(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of MA31536B1 publication Critical patent/MA31536B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR DES SELS D'AMINES D'ACIDE {4,6-BIS(DIMÉTHYLAMINO)-2-(4-(4-(TRIFLUOROMÉTHYL)BENZAMIDO)BENZYL)PYRIMIDIN-5-YL}-ACÉTIQUE, SUR DES PROCÉDÉS PERMETTANT DE LES PRÉPARER, SUR DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET SUR LEUR UTILISATION POUR LE TRAITEMENT, LA PRÉVENTION OU L'AMÉLIORATION D'UN OU PLUSIEURS SYMPTÔME D'UN TROUBLE OU D'UNE MALADIE À MÉDIATION PAR CRTH2.
MA32540A 2007-06-21 2010-01-19 Sels d'amines d'un antagoniste de crth2 MA31536B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93673607P 2007-06-21 2007-06-21

Publications (1)

Publication Number Publication Date
MA31536B1 true MA31536B1 (fr) 2010-07-01

Family

ID=39731477

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32540A MA31536B1 (fr) 2007-06-21 2010-01-19 Sels d'amines d'un antagoniste de crth2

Country Status (23)

Country Link
US (1) US8278310B2 (fr)
EP (1) EP2176240A1 (fr)
JP (1) JP6006914B2 (fr)
KR (1) KR20100039350A (fr)
CN (4) CN102898381A (fr)
AR (1) AR067118A1 (fr)
BR (1) BRPI0812597A2 (fr)
CA (1) CA2690436A1 (fr)
CL (1) CL2008001817A1 (fr)
CO (1) CO6251286A2 (fr)
EC (1) ECSP109851A (fr)
HK (1) HK1144940A1 (fr)
IL (1) IL202755A0 (fr)
MA (1) MA31536B1 (fr)
MX (1) MX2009013813A (fr)
MY (1) MY149005A (fr)
NZ (1) NZ581856A (fr)
RU (1) RU2468013C2 (fr)
TN (1) TN2009000517A1 (fr)
TW (1) TWI419693B (fr)
UA (1) UA101326C2 (fr)
WO (1) WO2008156781A1 (fr)
ZA (1) ZA200909110B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
CA2735722A1 (fr) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals, Inc. Derives d'acide pyrimidin-5-ylacetique enrichis en isotopes en tant qu'antagonistes de crth2
WO2010089391A1 (fr) * 2009-02-09 2010-08-12 Boehringer Ingelheim International Gmbh Nouvelles compositions pharmaceutiques destinées au traitement de troubles respiratoires et gastro-intestinaux
EP2451787B1 (fr) 2009-07-06 2013-04-24 Boehringer Ingelheim International GmbH Polymorphe de [4,6-bis(diméthylamino)-2-(4-{[4-(trifluorométhyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acétique
CA2781610A1 (fr) * 2009-11-24 2011-06-03 Boehringer Ingelheim International Gmbh Procede de preparation d'un polymorphe de sel de choline de derive d'acide pyrimidin-5-yl acetique
JP2013512239A (ja) 2009-11-24 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリミジン−５−イル酢酸誘導体の新規な塩の形態
JP2013535456A (ja) * 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
EP2598145A1 (fr) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Composition pharmaceutique pour le traitement de maladies respiratoires et inflammatoires
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
EA026456B1 (ru) 2011-12-16 2017-04-28 Атопикс Терапьютикс Лимитед Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
EP3108460A1 (fr) 2014-02-18 2016-12-28 Bekey A/S Contrôle d'accès à un emplacement
RU2019128534A (ru) 2017-02-15 2021-03-16 Наньян Текнолоджикал Юниверсити Химические соединения для лечения туберкулеза

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1280522E (pt) * 2000-04-26 2005-02-28 Warner Lambert Co Combinacao de eteres carboxialquilicos com anti-hipertensores e a utilizacao farmaceutica
US7078690B2 (en) * 2002-02-04 2006-07-18 Applied Materials, Israel, Ltd. Monitoring of contact hole production
PT1471057E (pt) * 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2006109836A1 (fr) * 2005-04-07 2006-10-19 Teijin Pharma Limited Cristal de dérivé d’aminopyrrolidine et méthode de synthèse dudit cristal
JP2010530425A (ja) * 2007-06-21 2010-09-09 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストの粒子
CA2735722A1 (fr) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals, Inc. Derives d'acide pyrimidin-5-ylacetique enrichis en isotopes en tant qu'antagonistes de crth2

Also Published As

Publication number Publication date
CN101772489A (zh) 2010-07-07
CN102875478A (zh) 2013-01-16
RU2010101795A (ru) 2011-07-27
AU2008266854A1 (en) 2008-12-24
AR067118A1 (es) 2009-09-30
ECSP109851A (es) 2010-03-31
CN102898380A (zh) 2013-01-30
MX2009013813A (es) 2010-02-03
JP2010530426A (ja) 2010-09-09
CA2690436A1 (fr) 2008-12-24
UA101326C2 (en) 2013-03-25
ZA200909110B (en) 2011-03-30
US20110034482A1 (en) 2011-02-10
HK1144940A1 (en) 2011-03-18
CL2008001817A1 (es) 2009-03-13
TWI419693B (zh) 2013-12-21
CN102898381A (zh) 2013-01-30
BRPI0812597A2 (pt) 2015-02-18
TW200911261A (en) 2009-03-16
IL202755A0 (en) 2010-06-30
JP6006914B2 (ja) 2016-10-12
MY149005A (en) 2013-06-28
CN101772489B (zh) 2013-02-20
NZ581856A (en) 2011-05-27
WO2008156781A1 (fr) 2008-12-24
EP2176240A1 (fr) 2010-04-21
RU2468013C2 (ru) 2012-11-27
US8278310B2 (en) 2012-10-02
CO6251286A2 (es) 2011-02-21
TN2009000517A1 (en) 2011-03-31
KR20100039350A (ko) 2010-04-15

Similar Documents

Publication Publication Date Title
MA31536B1 (fr) Sels d'amines d'un antagoniste de crth2
MA31534B1 (fr) Particules d'antagoniste de crth2
RU2427573C2 (ru) Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1)
Liu et al. 5‐HT6 antagonists as potential treatment for cognitive dysfunction
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA42145B1 (fr) Triazoles agonistes du récepteur apj
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
UA96764C2 (ru) Производные бензимидазола, полезные в лечении расстройств, связанных с рецептором trpvl
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
PE20121313A1 (es) Derivados de 4-aminociclohexano sustituidos
NO20075087L (no) Kombinasjoner, metoder og sammensetninger for behandling av cancer
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
DK1497279T3 (da) Substituerede indoler og deres anvendelse som 5HT-reuptake-inhibitorer og som 5HT-ligander
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
UY29219A1 (es) Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
TN2011000252A1 (fr) Lactames servant d'inhibiteurs de beta-secretase
SI2185155T1 (en) Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors
MA30556B1 (fr) COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE.
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
EA200601461A1 (ru) Новые производные бензил(иден)лактама
MA43313B1 (fr) Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation